allogeneic CAR iNKT-cell therapy 2 (Kite Pharma/Appia Bio)

N/A

Report date: 2025/01/26 18:22:15

Base Information

Drug Nameallogeneic CAR iNKT-cell therapy 2 (Kite Pharma/Appia Bio)
Drug Alias NameHSC-derived CAR-iNKT therapy (Kite Pharma/Appia Bio)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionNatural killer T-lymphocyte stimulantsT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKite Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAppia Bio IncKite Pharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A